Regional Factors Driven By Genetic Diversity Add Complexity To Autoimmune Disease Drug Development

As a group, autoimmune diseases remain one of the most refractory and difficult-to-treat segments of healthcare therapeutics. The underlying genetics of the immune response and the complexities they foster among individual patients make this one of the most challenging areas in all of life science. Until recently, autoimmune disease patients were given little hope for effective treatment. But the convergence of improved elucidation of autoimmune disease mechanisms and the ability to design and manufacture recombinant proteins capable of attenuating the immune system cascade has led to systemic treatments that have demonstrated the ability to provide some degree of relief from autoimmune symptoms in a significant number of patients. Perhaps more than any other disease segment, autoimmune conditions and the companies that... [read full story]